Does Disclosing Cannabis Use Affect ER Opioid Prescribing?

For someone arriving at an emergency department with a painful injury, mentioning cannabis use may come with an uncomfortable question: will this change how seriously the clinician takes their pain or what medication they receive?

A new study offers a cautiously reassuring finding. Researchers examining emergency department records found no clear independent association between documented cannabis disclosure and opioid prescriptions at discharge after accounting for measured patient and clinical differences. Prescribed opioid doses also showed no clear adjusted difference.

The study, Cannabis Use Disclosure and Opioid Prescribing at Emergency Department Discharge, was accepted by the Journal of Emergency Medicine in October 2026 and is available as a journal pre-proof.¹ Its contribution is specific but valuable: it examines a real prescribing decision at the intersection of cannabis use, acute pain, and patient communication.

What the Cannabis Disclosure Study Examined

The researchers reviewed records from a Southern California healthcare system between 2021 and 2023. Their analysis included 3,159 adults treated for selected painful conditions, including major or long-bone fractures, acute low-back and sciatic conditions, and certain minor musculoskeletal injuries.

Only each patient’s earliest eligible emergency visit was included. This prevented people with repeated visits from contributing multiple encounters to the primary analysis.

Of those patients, 507, or 16%, had documented cannabis use disclosure. The comparison group consisted of patients documented as not using cannabis, rather than everyone without an affirmative cannabis entry.

The main outcome was whether patients received an opioid prescription when leaving the emergency department. Among those prescribed an opioid, the researchers also examined total and daily morphine milligram equivalents, or MME. This measure allows different opioid medications to be compared on a common potency scale.

Why the Adjusted Findings Matter

The initial percentages might suggest that patients disclosing cannabis use were less likely to receive opioids. However, the absolute difference was approximately 3.6 percentage points, and its confidence interval included no difference.

More importantly, the patient groups were not interchangeable. Prescribing decisions can reflect the injury involved, pain severity, age, other substance use, and numerous additional considerations.

The researchers adjusted for demographic, clinical, substance-use, utilization, year, and diagnosis variables. After that adjustment, cannabis disclosure was not clearly associated with whether an opioid prescription was issued. Clinical condition was strongly associated with prescribing patterns.

This distinction protects against an appealing but unsupported headline. The study does not establish that telling a clinician about cannabis use reduces access to pain medication. It also does not establish that cannabis users need fewer opioids.

The confidence interval around the adjusted prescribing estimate remains compatible with different possibilities. Finding no statistically clear association is not the same as proving that the groups receive identical treatment.

Cannabis Disclosure Is Different From Cannabis Pain Relief

One of the most useful aspects of this research is the boundary it draws around its own question.

A discharge prescription records a clinician’s decision. It does not show whether the patient filled that prescription, how many tablets they took, whether their pain improved, or whether cannabis changed their recovery.

That makes this study different from research examining cannabis use to manage opioid withdrawal, which MyCannabis covered in July 2026. That research concerned people using unregulated opioids and their self-reported reductions in use. It addressed a different population, purpose, and outcome.

Similarly, reports of opioid reduction in chronic back pain concern longer-term treatment patterns. They cannot directly answer what should happen when someone arrives with a fresh fracture.

These distinctions allow promising findings to coexist without forcing them into a single narrative. Cannabis might eventually prove useful for particular patients or treatment goals, while disclosure alone shows little measurable association with prescribing in another setting.

Patient Trust Is a Separate Clinical Question

The broader opportunity lies in making cannabis discussions routine enough that patients can provide useful information without assuming they will be judged.

A 2026 review of cannabis stigma and disclosure among older adults examined anticipated stigma as a barrier to communication in healthcare settings. That is a different research question from opioid prescribing, but it helps explain why disclosure deserves attention in its own right.

The emergency department study did not measure whether patients felt respected, whether they withheld information, or whether clinicians expressed negative attitudes. It therefore cannot demonstrate that cannabis-related stigma was absent.

Nevertheless, its findings provide a constructive starting point. Within this healthcare system and these selected conditions, documented cannabis disclosure was not independently associated with a clear difference in the measured discharge prescribing outcomes.

That gives clinicians and patient advocates something more useful than a blanket promise: evidence that can support a more informed conversation while acknowledging that experiences vary.

Useful Cannabis Information Goes Beyond Yes or No

For treatment planning, a simple cannabis-use checkbox leaves substantial information missing. An occasional low-dose edible and frequent use of a high-THC concentrate represent different exposure patterns, even if both generate the same entry in a medical record.

A more informative discussion can cover:

• The product used and its labeled THC and CBD content.
• How much is used, how often, and when it was last taken.
• The reason for use and other medications or substances involved.

Health Canada’s medical cannabis information, updated in January 2026, emphasizes discussing cannabis with healthcare providers and identifying other substances being taken. It notes potential interactions with several medication categories, including products that cause dizziness or drowsiness.

The practical value of disclosure therefore extends beyond whether an opioid is prescribed. It helps establish the medication history needed to assess treatment options and explain precautions.

Why Missing Cannabis Records Matter

The study’s most consequential limitation may be the patients who could not enter the primary comparison.

Another 1,634 otherwise eligible patients had cannabis status recorded as missing, deferred, or not asked. Those patients were excluded from the primary analysis.

If cannabis documentation differed according to the patient’s circumstances or the clinician’s approach, the included sample could differ systematically from the broader emergency department population. The authors identify this as a potential source of selection bias.

There were other gaps. Records did not establish cannabis dose, frequency, route, duration, cannabinoid composition, or timing relative to the visit. Medical and recreational use were not distinguished.

Information about prior outpatient opioid exposure, prescription-monitoring findings, provider characteristics, and detailed prescribing reasoning was also incomplete. Statistical adjustment cannot fully compensate for information that was never captured.

Finally, this was one healthcare system in Southern California. Its results may not transfer directly to regions with different cannabis laws, prescribing practices, or attitudes toward disclosure.

Better Pain Care Needs Better Outcomes

A valuable next step would be to connect prescribing records with what happens after discharge.

Did the patient obtain adequate relief? Could they sleep, move, and return to daily activities? Did medication cause unwanted effects? Did they understand how to use it safely?

Those questions matter because a lower prescription rate is not automatically evidence of better care. Neither is a higher rate. The appropriate outcome depends on the condition, the patient’s needs, and the balance of benefits and risks.

The CDC’s patient guidance on prescription opioids, published in June 2025, emphasizes individualized pain management, treatment goals, and open discussion of medication risks and alternatives.

Future cannabis research could build on that approach by measuring both treatment decisions and recovery. Prospective studies across multiple healthcare systems could also document cannabis exposure consistently and examine how disclosure enters clinical reasoning.

For now, this study supports a measured message: documented cannabis disclosure was not clearly associated with different discharge opioid prescribing after adjustment. Its broader promise is a healthcare conversation in which cannabis becomes useful clinical information, helping patients and clinicians make better-informed decisions together.

References:

¹ Clobes, T. A., Kraybill, M., Himebaugh, S., Jones, B., & Jaskolka, M. (2026). Cannabis use disclosure and opioid prescribing at emergency department discharge. Journal of Emergency Medicine. Advance online publication. https://doi.org/10.1016/j.jemermed.2026.10.001